Navigation Links
Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
Date:1/3/2008

dies further support continued development of ANA598 as a candidate for use in combination with other agents for the treatment of chronic HCV infection."

In June 2007, Anadys announced the nomination of ANA598 as a clinical development candidate. The selection of ANA598 represented the culmination of a comprehensive structure-based drug design program directed towards NS5B. ANA598 was selected based on an optimized balance of preclinical properties, including intrinsic potency as an NS5B inhibitor, cellular activity in the replicon assay, oral bioavailability and early indicators of safety and tolerability. ANA598 is a low-nanomolar inhibitor of HCV genotype 1a and 1b replicons. It exhibits good in vitro metabolic stability properties and does not significantly inhibit or induce cytochrome P450 enzymes. In vivo, ANA598 was well tolerated in 14-day dose range finding (DRF) animal toxicology studies. At doses corresponding to estimated human doses, 24 hour trough plasma concentrations of ANA598 exceeded the EC95 for HCV genotype 1a and 1b replicon inhibition. The EC95 is the concentration required in vitro to suppress hepatitis C viral RNA levels by 95% in the replicon assay.

ANA598 is currently completing IND enabling activities and an IND submission is targeted for the second quarter of 2008. "After completing the necessary IND enabling studies, we look forward to exploring the potential clinical utility of ANA598," said James Freddo, MD, Anadys' Chief Medical Officer. "Based on the in vitro and in vivo potency, pharmacokinetic and preliminary toxicologic properties of ANA598 demonstrated to date, we believe that this is an exciting new direct antiviral to investigate for the treatment of patients with hepatitis C virus infection."

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome
3. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
4. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
5. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
6. Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
7. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
8. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
9. Vion Pharmaceuticals To Present Preliminary Data on its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) at the American Society of Hematology Meeting
10. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Stem Cell Transplantation
11. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
(Date:7/9/2014)... scientific research into the metabolism of stromal support cells ... metabolism of these cell types in the development of ... inflammatory conditions and cancer. That was the conclusion of ... Leuven in the leading journal Nature . , ... of wake-up call. The metabolism of cancer cells has ...
(Date:7/9/2014)... R.I. Researchers have found that fecal transplantation ... in immunocompromised patients. This is the result of ... in the Center for Women,s Gastrointestinal Medicine at The ... been published online in advance of print in the ... difficile , or C. diff , has increased ...
(Date:7/9/2014)... R.I. -- Researchers from The Miriam Hospital ... disease (COPD) who are also depressed have difficulty ... to be particularly true for women, and screening ... as part of treatment. The study and its ... Medicine . , Chronic obstructive pulmonary disease ...
(Date:7/9/2014)... available in French . ... year old teens, including brain structure and function, personality, life ... will go on to develop binge drinking within the next ... other variables such as life events and a family history ... Whether or not the child had had a single ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:Wake-up call for more research into cell metabolism 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Miriam Hospital study examines effect of depressed mood on pulmonary rehab completion 2Health News:What drives a child to abuse alcohol? 2
... the big gameMINNEAPOLIS, Jan. 29 The Super Bowl ... it is for the actual football game. Among this ... Minnesota that somberly reminds Minnesotans that "we all pay ... consequences of tobacco use are explored though a series ...
... bugs" because our antibiotic arsenal has run dry, leaving the ... disease researchers at The University of Texas Medical School at ... New England Journal of Medicine , Barbara E. Murray, M.D., ... future response to preventing and treating "super bugs." , A ...
... National Family Planning and Reproductive Health AssociationWASHINGTON, Jan. 28 ... planning services makes sense. According to the Congressional ... SAVE the federal government more than $200 million over ... the rumors and inaccuracies that have flooded America,s airwaves ...
... Cream Moves from Athletic Roots to Help Arthritis PainPLEASANT ... season, a toxin-free pain relief cream was ... Brady, Willie McGinest and LaDainian Tomlinson. The pain ... and muscles. The idea was to help players ...
... kind finds no health downside to donation , , WEDNESDAY, Jan. ... life by donating a kidney tend to lead long, healthy ... follow-up of donors ever conducted. , "Their lifespan is comparable ... said study author Dr. Hassan N. Ibrahim, an associate professor ...
... January 28, 2009 A new study has found ... spinal cord, called ependymal stem cells, reverses paralysis associated with ... the population of these cells after spinal cord injury was ... The results open a new window on spinal cord regenerative ...
Cached Medicine News:Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 2Health News:New Super Bowl Ad Reminds Minnesotans: 'We All Pay the Price for Tobacco' 3Health News:Call to action: Running out of options to fight ever-changing 'super bugs' 2Health News:Call to action: Running out of options to fight ever-changing 'super bugs' 3Health News:Get the Facts the House Republicans Don't Want You to Have 2Health News:Pro Football Healthcare Generates Arthritis Pain Relief Cream 2Health News:Most Kidney Donors Lead Long, Healthy Lives 2Health News:Most Kidney Donors Lead Long, Healthy Lives 3Health News:Stem cells used to reverse paralysis in animals 2
A rapid, convenient, qualitative method for detecting asymptomatic occult bleeding....
... die each year of colon cancer ... improvements (high contrast berium enema, colonoscopy, ... in the success rate of curative ... been achieved over the past two ...
... use of guaiac as a test for the ... of phenolic compounds present in guaiac to quinones, ... If blood is present, the heme portion of ... manner, catalyzing the release of oxygen from hydrogen ...
... SENSA elitewas designed to improve patient compliance. ... and sample collection options make this fecal ... understand and complete. Diet guidelines are explained ... determine which foods and drugs are okay ...
Medicine Products: